Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Filings indexed 1,720 across all filing types
Latest filing 2024-02-05 Annual Report
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2023
2024-02-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-02-02 English
PRIMARY DOCUMENT
Director's Dealing
2024-02-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Regeneron Pharmaceuticals, Inc. dated February 2, 2024. It announces the issuance of a press release reporting the financial and operating results for the quarter and year ended December 31, 2023. The document itself does not contain the full financial statements or detailed financial data but rather furnishes the press release as an exhibit. The text explicitly states that the information is being furnished and incorporated by reference, and it is a current report rather than a full earnings release or annual report. Given the short length (3659 characters) and the nature of the document as a current report announcing the release of financial results, this fits the definition of an Earnings Release (ER) announcement. However, since the document is the Form 8-K furnishing the press release and not the press release itself, and it contains the key highlights of financial results, the best classification is Earnings Release (ER).
2024-02-02 English
Regulatory Filings 2024
Regulatory Filings
2024-02-01 English
Regulatory Filings 2024
Regulatory Filings
2024-02-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.